Precision Oncology Executive Cancer Caregiver Philanthropreneur

Sherin Al-Safadi, MSc, MBA, PhD VP Medical & Corporate Affairs, Radiopharm Theranostics (ASX: RAD), Precision Oncology Executive Cancer Caregiver Philanthropreneur, Guinness Record Holder Reference: Hitting the mark: A roadmap for overcoming translational challenges in Radioligand Therapies Radioligand therapy (RLT) is quickly emerging as the new cornerstone of cancer care, and as with other oncology treatments that are in development, is no stranger to key translational obstacles. This talk, entitled "Hitting the mark: A roadmap for overcoming translational challenges in RLTs", explores the key strategies that can successfully reconcile divergences between preclinical research and clinical realities for accelerating the development of clinically effective RLTs. Essential considerations include radionuclide properties and supply, novel targeting moieties, theranostic pairs, personalized dosimetry estimates, and the potential for safe and well-tolerated combination therapies earlier in the cancer treatment paradigm. RLT represents a big step forward in the era of precision oncology and provides a new tool in the HCP armamentarium for improved clinical outcomes in patients who have no remaining treatment options.